首页> 外国专利> CYP3A7 3'UTR Method to predict the blood concentration of tacrolimus using SNP in 3'UTR of CYP3A7

CYP3A7 3'UTR Method to predict the blood concentration of tacrolimus using SNP in 3'UTR of CYP3A7

机译:CYP3A7 3'UTR用SNP预测CYP3A7 3'UTR中他克莫司的血药浓度的方法

摘要

The present invention relates to a method for predicting a drug concentration of an entity with respect to tacrolimus. More specifically, the present invention relates to a composition for predicting a drug concentration of an entity with respect to tacrolimus, wherein the composition includes rs10211 single nucleotide polymorphism (SNP) disposed at CYP3A7; a kit for detecting the SNP; and a method for predicting a drug concentration of an entity with respect to tacrolimus by analyzing a haplotype with respect to the SNP. According to the present invention, a drug concentration of an entity with respect to tacrolimus is predicted in advance according to a genetic difference of entities, so the present invention can be useful in determining a suitable administration amount with respect to tacrolimus. Accordingly, a drug concentration in blood can be made to rapidly reach a suitable treatment region in an early stage, and the occurrence of early rejection and drug side effects is reduced. Thus, the present invention is very useful in ensuring effectiveness and safety of tacrolimus.
机译:本发明涉及预测他克莫司的实体药物浓度的方法。更具体地,本发明涉及用于预测他克莫司的实体药物浓度的组合物,其中该组合物包括置于CYP3A7的rs10211单核苷酸多态性(SNP);用于检测SNP的试剂盒;通过对单核苷酸多态性(SNP)进行单倍型分析来预测他克莫司相对于实体的药物浓度的方法。根据本发明,根据实体的遗传差异预先预测实体相对于他克莫司的药物浓度,因此本发明可用于确定相对于他克莫司的合适给药量。因此,可以使血液中的药物浓度在早期迅速达到合适的治疗区域,并且减少了早期排斥反应和药物副作用的发生。因此,本发明对于确保他克莫司的有效性和安全性非常有用。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号